Rise and shine, everyone, another busy day is on the way. Yes, indeed, the middle of the week is already here, which means there is much to do. No doubt, you can relate on some level. So please join us as we grab a needed cup of stimulation — our choice today is maple pecan — and tackle the online calls and deadlines that are piling up. Meanwhile, here is the latest grab of items of interest to help you along. Hope you conquer the world today and do stay in touch …
GlaxoSmithKline (GSK) will receive $1.25 billion and royalties from Gilead Sciences (GILD) as part of a settlement ending a long-drawn patent dispute involving its ViiV Healthcare unit, Pharmaphorum notes. The dispute centered on Gilead’s Biktarvy HIV antiretroviral drug, which ViiV claimed infringed on patents for dolutegravir and other similar compounds developed by ViiV. Biktarvy, which combines three HIV medicines in a single daily tablet, poses the biggest competitive challenge for ViiV and is one of Gilead’s top-selling treatments, bringing in sales of $7.05 billion in 2021 from the U.S. market.
The U.S. government is spending about $530 for each five-day course of the Pfizer (PFE) Covid-19 pill, Paxlovid, but the contract for the first 10 million doses would allow the government to get a lower price if one of a handful of other wealthy countries gets a better deal on the drug, NPR tells us. This is part of a purchase agreement that seems to be more favorable to the federal government overall compared to the Covid-19 vaccine contracts. The contract has something called most favored nation pricing but is limited to price comparisons with a handful of other wealthy countries.
Create a display name to comment
This name will appear with your comment